Innovative Applications of Extracorporeal Photopheresis in Solid Organ Transplantation

Project Information

exTra

Grant agreement ID: 101119855

DOI

10.3030/101119855

EC signature date 13 July 2023

Start date 1 September 2023

End date 31 August 2027

Funded under

• Marie Skłodowska-Curie Actions (MSCA)

Total cost

No data

EU contribution

€ 2 613 103,20

Coordinated by

KLINIKUM DER UNIVERSITAET REGENSBURG
Germany

Periodic Reporting for period 1 - exTra (Innovative Applications of Extracorporeal Photopheresis in Solid Organ Transplantation)

Reporting period: 2023-09-01 to 2025-08-31

Summary of the context and overall objectives of the project

Organ transplantation saves and transforms lives, but long-term success remains limited by immune rejection and the side effects of lifelong immunosuppressive drugs. While short-term outcomes have improved greatly, many patients still experience gradual loss of organ function, chronic inflammation, or serious complications caused by standard therapies. Therefore, there is an urgent need for innovative, patient-tailored approaches that can better control the immune system while reducing treatment burden.
The EU-funded doctoral network exTra (Innovative Applications of Extracorporeal Photopheresis in Solid Organ Transplantation) addresses this challenge by exploring the potential of extracorporeal photopheresis (ECP), a personalised immune-modulating therapy already used in selected transplant settings. exTra aims to deepen understanding of how ECP works, identify where it could be most beneficial, and lay the foundations for its wider and more effective use across different types of organ transplantation.
Beyond its scientific goals, the exTra network is a highly integrated European training network. It brings together universities, hospitals, research institutes, industry partners, and clinicians to train a new generation of doctoral researchers with the interdisciplinary skills needed to translate complex biomedical research into real-world clinical impact.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

exTra combines basic research, translational studies, and clinical insight across several complementary research themes. Researchers within the network investigate how ECP influences immune regulation, antibody-mediated responses, tissue repair, and treatment optimisation in different transplant contexts, including kidney, liver, lung, and heart transplantation.
A major achievement of the project is the coordinated investigation of ECP from multiple perspectives. Experimental models, patient samples, advanced molecular analyses, and computational approaches are used in parallel, allowing discoveries in one area to inform progress in others. This collaborative structure ensures that knowledge is shared efficiently across institutions and disciplines.
At the same time, exTra places strong emphasis on doctoral training. Doctoral candidates receive joint supervision, participate in secondments across Europe, and engage in network-wide courses on topics such as data management, reproducible science, regulatory pathways, ethics, and science communication. Many have already contributed to peer-reviewed publications and international conferences, demonstrating both scientific progress and professional development.

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

Rather than focusing on a single mechanism or disease, exTra advances the field by taking a broad view of immune modulation in transplantation. The project moves beyond “one-size-fits-all” immunosuppression by exploring how therapies like ECP may promote immune balance, support tissue healing, and reduce harmful immune responses without generally suppressing immunity.
exTra also contributes methodological advances, including improved experimental models, harmonised laboratory protocols, and innovative approaches to immune monitoring. These developments help create a more robust and reproducible framework for studying complex immune therapies.
Importantly, the project strengthens the bridge between discovery science and clinical application. By integrating academic research with industrial expertise and clinical practice, exTra helps ensure that new insights are compatible with real-world healthcare needs, regulatory requirements, and future innovation pathways.

whatsapp-image-2026-01-16-at-16-29-52.jpeg